Wells Fargo & Company Upgrades Solventum (NYSE:SOLV) to Hold

Solventum (NYSE:SOLV) was upgraded by equities research analysts at Wells Fargo & Company to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

SOLV has been the subject of several other research reports. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Mizuho set a $100.00 target price on Solventum and gave the company an “outperform” rating in a report on Tuesday, January 20th. Piper Sandler reaffirmed an “overweight” rating on shares of Solventum in a research report on Wednesday, December 17th. UBS Group reiterated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. Finally, BTIG Research reissued a “buy” rating and issued a $100.00 price objective on shares of Solventum in a research report on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat.com, Solventum presently has an average rating of “Moderate Buy” and an average price target of $93.70.

Solventum Stock Performance

NYSE:SOLV opened at $67.18 on Wednesday. The firm has a market capitalization of $11.66 billion, a PE ratio of 7.57, a PEG ratio of 1.13 and a beta of 0.40. Solventum has a 1 year low of $60.70 and a 1 year high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The firm’s fifty day simple moving average is $75.50 and its 200 day simple moving average is $75.88.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same quarter in the previous year, the business earned $1.41 EPS. The business’s revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, sell-side analysts anticipate that Solventum will post 6.58 EPS for the current year.

Solventum announced that its Board of Directors has authorized a stock repurchase plan on Thursday, November 20th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Insider Transactions at Solventum

In other Solventum news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares of the company’s stock, valued at approximately $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is owned by company insiders.

Institutional Investors Weigh In On Solventum

A number of institutional investors have recently added to or reduced their stakes in the stock. Assetmark Inc. raised its holdings in shares of Solventum by 21.4% in the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after buying an additional 128 shares in the last quarter. Hilltop National Bank boosted its stake in Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares in the last quarter. Allworth Financial LP grew its position in Solventum by 2.8% in the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after acquiring an additional 129 shares during the period. CIBC Private Wealth Group LLC grew its position in Solventum by 0.5% in the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after acquiring an additional 134 shares during the period. Finally, BOKF NA raised its stake in Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after acquiring an additional 141 shares in the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.